1-ethoxycarbonyl-4-hydroxy-(4-nitromethyl)piperidine | 106244-73-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-ethoxycarbonyl-4-hydroxy-(4-nitromethyl)piperidine
• 英文别名: ethyl 4-hydroxy-4-(nitromethyl)piperidine-1-carboxylate；ethyl 4-hydroxy-4-(nitromethyl)-1-piperidinecarboxylate
• CAS: 106244-73-9
• 化学式: C₉H₁₆N₂O₅
• 分子量: 232.236
• InChiKey: REWMGYLEJYCGAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  95.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-ethoxycarbonyl-4-hydroxy-(4-nitromethyl)piperidine 在 氢氧化钯 crude material 、 氢氧化钯 作用下， 以 乙醇 为溶剂， 反应 29.0h， 以to provide ethyl 4-(aminomethyl)-4-hydroxypiperidine-1-carboxylate, which的产率得到ethyl 4-(aminomethyl)-4-hydroxy-1-piperidinecarboxylic acid ester
  参考文献：
  名称：

  SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES

  摘要：

  本发明涉及在1-位置被环状取代的咪唑喹啉、吡啶、萘啶环系统（特别是喹啉、四氢喹啉、吡啶、[1,5] 萘啶、[1,5] 四氢萘啶），以及含有这些化合物的制药组合物、制备这些化合物的方法，以及将这些化合物用作免疫调节剂、诱导动物细胞因子生物合成和治疗包括病毒和肿瘤疾病的方法。

  公开号：

  US20110092477A1
• 作为产物：
  描述：

  N-乙氧羰基-4-哌啶酮 在 sodium methylate 作用下， 以 甲醇 、 硝基甲烷 、 Petroleum ether 为溶剂， 生成 1-ethoxycarbonyl-4-hydroxy-(4-nitromethyl)piperidine
  参考文献：
  名称：

  Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed

  摘要：

  新型替代N-[(4-哌啶基)烷基]的环状氧唑和噻唑胺类化合物可用作抗抑郁药，在帕金森病的治疗以及与肠动力紊乱相关疾病的治疗中有用。

  公开号：

  US04689330A1
• 作为试剂：
  描述：

  、 N-乙氧羰基-4-哌啶酮 、 硝基甲烷 、 sodium methylate 在 ice 、 氯仿 、 petroleum ether 、 1-ethoxycarbonyl-4-hydroxy-(4-nitromethyl)piperidine 作用下， 以 甲醇 为溶剂， 反应 18.0h， 以yielding 73 parts of ethyl 4-hydroxy-4-(nitromethyl)-1-piperidinecarboxylate (intermediate 3)的产率得到
  参考文献：
  名称：

  Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed

  摘要：

  这是一句英文的药物描述，翻译成中文如下： 新型替代的N-[(4-哌啶基)烷基]二环氧唑和噻唑胺，可用作抗抑郁药，在帕金森病的治疗和与肠动力失调相关的疾病的治疗中有用。

  公开号：

  US04749702A1

文献信息

• Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
  申请人：Bosmans Rene Marie Andre Jean-Paul

  公开号：US20060142341A1

  公开（公告）日：2006-06-29

  The present invention of compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, R 1 and R 2 taken together form a bivalent radical of formula wherein in said bivalent radicals one or two hydrogen atoms may be substituted with C 1-6 alkyl; R 3 is hydrogen or halo; R 4 is hydrogen or C 1-6 alkyl; R 5 is hydrogen or C 1-6 alkyl; L is C 3-6 cycloalkyl, C 5-6 cycloalkanone, C 2-6 alkenyl, or L is a radical of formula -Alk-R 6 —, Alk-X—R 7 , -Alk-Y—C(═O)—R 9 , or -Alk-Y—C(═O)—NR 11 R 12 wherein each Alk is C 1-12 alkanediyl; and R 6 is hydrogen, cyano, C 1-6 alkylsulfonylamino, C 3-6 cycloalkyl, C 5-6 cycloalkanone, or a heterocyclic ringsystem; R 7 is hydrogen, C 1-6 alkyl, hydroxyC 1-6 alkyl, C 3-6 cycloalkyl, or a heterocyclic ringsystem; X is O, S, SO 2 or NR 8 ; said R 8 being hydrogen or C 1-6 alkyl; R 9 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkyloxy or hydroxy; Y is NR 10 or a direct bond; said R 10 being hydrogen, or C 1-6 alkyl; R 11 and R 12 each independently are hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, or R 11 and R 12 combined with the nitrogen atom may form an optionally substituted pyrrolidinyl, piperidinyl, piperazinyl or 4-morpholinyl ring. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.

  本发明涉及式(I)化合物、其立体化学异构体、N-氧化物形式或其药学上可接受的酸加成盐，其中R1和R2结合形成式的二价基团，其中在所述的二价基团中，一个或两个氢原子可以被C1-6烷基替代；R3为氢或卤素；R4为氢或C1-6烷基；R5为氢或C1-6烷基；L为C3-6环烷基、C5-6环戊酮基、C2-6烯基，或L为式-Alk-R6-、Alk-X-R7、-Alk-Y-C(═O)-R9或-Alk-Y-C(═O)-NR11R12的基团，其中每个Alk为C1-12烷二基；R6为氢、氰基、C1-6烷基磺酰氨基、C3-6环烷基、C5-6环戊酮基或杂环环系统；R7为氢、C1-6烷基、羟基C1-6烷基、C3-6环烷基或杂环环系统；X为O、S、SO2或NR8，其中R8为氢或C1-6烷基；R9为氢、C1-6烷基、C3-6环烷基、C1-6烷氧基或羟基；Y为NR10或直接键，其中R10为氢或C1-6烷基；R11和R12各自独立地为氢、C1-6烷基、C3-6环烷基，或R11和R12与氮原子结合可以形成可选取代的吡咯烷基、哌啶基、哌嗪基或4-吗啉基环。揭示了制备所述产品的方法、包含所述产品的制剂以及其作为药物的用途，特别是用于治疗与胃排空障碍有关的疾病。
• Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
  申请人：——

  公开号：US20030078427A1

  公开（公告）日：2003-04-24

  The present invention of compounds of formula (I) 1 a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, R 1 is C 1-6 alkyloxy, C 2-6 alkenyloxy or C 2-6 alkynyl-oxy; R 2 is hydrogen, C 1-6 alkyl C 1-6 alkyloxy; R 3 is hydrogen or halo; R 4 is hydrogen or C 1-6 alkyl; R 5 is hydrogen or C 1-6 alkyl; L is C 3-6 cycloalkyl, C 5-6 cycloalkanone, C 2-6 alkenyl, or L is a radical of formula-Alk-R 6 —, Alk-X—R 7 , —Alk-Y—C(═O)—R 9 , or —Alk-Y—C(═O)—NR 11 R 12 wherein each Alk is C 1-12 alkanediyl; and R 6 is hydrogen, cyano, C 1-6 alkylsulfonylamino, C 3-6 cycloalkyl, C 5-6 cyclo-alkanone, or a heterocyclic ringsystem; R 7 is hydrogen, C 1-6 alkyl, hydroxyC 1-6 alkyl, C 3-6 cycloalkyl, or a heterocyclic ringsystem; X is O, S, SO 2 or NR 8 ; said R 8 being hydrogen or C 1-6 alkyl; R 9 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkyloxy or hydroxy; Y is NR 10 or a direct bond; said R 10 being hydrogen, or C 1-6 alkyl; R 11 and R 12 each independently are hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, or R 11 and R 12 combined with the nitrogen atom may form an optionally substituted pyrrolidinyl, piperidinyl, piperazinyl or 4-morpholinyl ring. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.

  本发明涉及式（I）化合物，其立体化学异构体形式，其N-氧化物形式或其药学上可接受的酸加成盐，其中R1为C1-6烷氧基，C2-6烯氧基或C2-6炔氧基；R2为氢，C1-6烷基或C1-6烷氧基；R3为氢或卤素；R4为氢或C1-6烷基；R5为氢或C1-6烷基；L为C3-6环烷基，C5-6环戊酮，C2-6烯基，或L为式-Alk-R6—，Alk-X—R7，—Alk-Y—C(═O)—R9或—Alk-Y—C(═O)—NR11R12的基团，其中每个Alk为C1-12烷二基；R6为氢，氰基，C1-6烷基磺酰氨基，C3-6环烷基，C5-6环戊酮或杂环环系；R7为氢，C1-6烷基，羟基C1-6烷基，C3-6环烷基或杂环环系；X为O，S，SO2或NR8；其中R8为氢或C1-6烷基；R9为氢，C1-6烷基，C3-6环烷基，C1-6烷氧基或羟基；Y为NR10或直接键；其中R10为氢或C1-6烷基；R11和R12各自独立地为氢，C1-6烷基，C3-6环烷基，或R11和R12与氮原子结合可以形成可选择取代的吡咯烷基，哌啶基，哌嗪基或4-吗啉基环。公开了制备所述产品的过程，包含所述产品的配方以及其作为药物的用途，特别是用于治疗与胃排空障碍有关的疾病。
• Gastrokinetic monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
  申请人：Janssen Pharmaceutica N.V.

  公开号：US06452013B1

  公开（公告）日：2002-09-17

  The present invention of compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, R1 is C1-6alkyloxy, C2-6alkenyloxy or C2-6alkynyl-oxy; R2 is hydrogen, C1-6alkyl C1-6alkyloxy; R3 is hydrogen or halo; R4 is hydrogen or C1-6alkyl; R5 is hydrogen or C1-6alkyl; L is C3-6cycloalkyl, C5-6cycloalkanone, C2-6alkenyl, or L is a radical of formula —Alk—R6—, Alk—X—R7, -Alk-Y—C(═O)—R9, or -Alk-Y—C(═O)—NR11R12 wherein each Alk is C1-12alkanediyl; and R6 is hydrogen, cyano, C1-6alkylsulfonylamino, C3-6cycloalkyl, C5-6cycloalkanone, or a heterocyclic ringsystem; R7 is hydrogen, C1-6alkyl, hydroxyC1-6alkyl, C3-6cycloalkyl, or a heterocyclic ringsystem; X is O, S, SO2 or NR8; said R8 being hydrogen or C1-6alkyl; R9 is hydrogen, C1-6alkyl, C3-6cycloalkyl, C1-6alkyloxy or hydroxy; Y is NR10 or a direct bond; said R10 being hydrogen, or C1-6alkyl; R11 and R12 each independently are hydrogen, C1-6alkyl, C3-6cycloalkyl, or R11 and R12 combined with the nitrogen atom may form an optionally substituted pyrrolidinyl, piperidinyl, piperazinyl or 4-morpholinyl ring. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.

  本发明涉及式（I）化合物，其立体化学异构体形式，其N-氧化物形式或其药学上可接受的酸加成盐，其中R1是C1-6烷氧基，C2-6烯氧基或C2-6炔基氧基；R2是氢，C1-6烷基或C1-6烷氧基；R3是氢或卤素；R4是氢或C1-6烷基；R5是氢或C1-6烷基；L是C3-6环烷基，C5-6环烷酮，C2-6烯基，或L是式—Alk—R6—，Alk—X—R7，-Alk-Y—C（═O）—R9或-Alk-Y—C（═O）—NR11R12的基团，其中每个Alk是C1-12烷二基；R6是氢，氰基，C1-6烷基磺酰胺基，C3-6环烷基，C5-6环烷酮或杂环环系；R7是氢，C1-6烷基，羟基C1-6烷基，C3-6环烷基或杂环环系；X是O，S，SO2或NR8；其中R8是氢或C1-6烷基；R9是氢，C1-6烷基，C3-6环烷基，C1-6烷氧基或羟基；Y是NR10或直接键；其中R10是氢或C1-6烷基；R11和R12各自独立地是氢，C1-6烷基，C3-6环烷基，或R11和R12与氮原子结合可形成可选择取代的吡咯烷基，哌啶基，哌嗪基或4-吗啉基环。公开了制备所述产品的方法，包含所述产品的制剂以及它们作为药物的用途，特别是用于治疗与胃排空障碍有关的疾病。
• Substituted Imidazoquinolines, Imidazopyridines, and Imidazonaphthyridines
  申请人：Stoermer Doris

  公开号：US20070287724A1

  公开（公告）日：2007-12-13

  Imidazo-quinoline, -pyridine, and -naphthyridine ring systems (particularly quinolines, tetrahydroquinolines, pyridines, 1,5-naphthyridines, 1,5-tetrahydronaphthyridines) substituted at the 1-position with a cyclic substituent, pharmaceutical compositions containing the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

  本发明涉及在1位取代有环状取代基的咪唑喹啉、吡啶和萘啶环系统（特别是喹啉、四氢喹啉、吡啶、1,5-萘啶和1,5-四氢萘啶），以及含有这些化合物的制药组合物，以及将这些化合物用作免疫调节剂的方法，用于诱导动物中的细胞因子生物合成以及治疗包括病毒和肿瘤性疾病在内的疾病。
• Gastrokinetic monocyclic benzamides of 3-or 4-substituted 4-(aminoethyl)-piperidine derivatives
  申请人：Janssen Pharmaceutics, N.V.

  公开号：US06750349B2

  公开（公告）日：2004-06-15

  The present invention of compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, R1 is C1-6alkyloxy, C2-6alkenyloxy or C2-6alkynyl-oxy; R2 is hydrogen, C1-6alkyl C1-6alkyloxy; R3 is hydrogen or halo; R4 is hydrogen or C1-6alkyl; R5 is hydrogen or C1-6alkyl; L is C3-6cycloalkyl, C5-6cycloalkanone, C2-6alkenyl, or L is a radical of formula —Alk—R6—, Alk-X—R7, —Alk—Y—C(═O)—R9, or —Alk—Y—C(═O)—NR11R12 wherein each Alk is C1-12alkanediyl; and R6 is hydrogen, cyano, C1-6alkylsulfonylamino, C3-6cycloalkyl, C5-6cycloalkanone, or a heterocyclic ringsystem; R7 is hydrogen, C1-6alkyl, hydroxyC1-6alkyl, C3-6cycloalkyl, or a heterocyclic ringsystem; X is O, S, SO2 or NR8; said R8 being hydrogen or C1-6alkyl; R9 is hydrogen, C1-6alkyl, C3-6cycloalkyl, C1-6alkyloxy or hydroxy; Y is NR10 or a direct bond; said R10 being hydrogen, or C1-6alkyl; R11 and R12 each independently are hydrogen, C1-6alkyl, C3-6cycloalkyl, or R11 and R12 combined with the nitrogen atom may form an optionally substituted pyrrolidinyl, piperidinyl, piperazinyl or 4-morpholinyl ring. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.

  本发明涉及公式(I)的化合物及其立体化学异构体，N-氧化物形式或其药学上可接受的酸加成盐，其中R1为C1-6烷氧基，C2-6烯氧基或C2-6炔基氧基；R2为氢，C1-6烷基或C1-6烷氧基；R3为氢或卤素；R4为氢或C1-6烷基；R5为氢或C1-6烷基；L为C3-6环烷基，C5-6环戊酮，C2-6烯基，或L为公式-Alk-R6-，Alk-X-R7，-Alk-Y-C（═O）-R9或-Alk-Y-C（═O）-NR11R12的基团，其中每个Alk为C1-12烷二基；R6为氢，氰基，C1-6烷基磺酰氨基，C3-6环烷基，C5-6环戊酮或杂环环系；R7为氢，C1-6烷基，羟基C1-6烷基，C3-6环烷基或杂环环系；X为O，S，SO2或NR8；其中R8为氢或C1-6烷基；R9为氢，C1-6烷基，C3-6环烷基，C1-6烷氧基或羟基；Y为NR10或直接键；其中R10为氢或C1-6烷基；R11和R12各自独立地为氢，C1-6烷基，C3-6环烷基，或R11和R12与氮原子结合可形成可选取代的吡咯烷基，哌啶基，哌嗪基或4-吗啉基环。本发明还揭示了制备上述产品的过程，包括包含上述产品的制剂以及其作为药物的用途，特别是用于治疗与胃排空障碍有关的疾病。